Prenatal diagnosis of mucopolysaccharidosis type VII facilitating treatment in neonatal period

Abstract

AbstractDuo exome testing was performed on a fetus conceived via in vitro fertilization with an egg donor. The fetus presented with non‐immune hydrops fetalis (NIHF) at 20 + 0 weeks gestation. Two variants were detected in the GUSB gene. Biallelic pathogenic variants cause mucopolysaccharidosis type VII (MPS‐VII), which can present with NIHF prenatally. At the time of analysis and initial report, one variant was classified as likely pathogenic and the other as of uncertain clinical significance. Biochemical testing of the amniotic fluid supernatant showed elevated glycosaminoglycans and low β‐glucuronidase activity consistent with the diagnosis of MPS‐VII. This evidence allowed the upgrade of the pathogenicity for both variants, confirming the diagnosis of MPS‐VII. The infant was born at 36 + 5 weeks and enzyme replacement therapy (ERT) using vestronidase was initiated at 20 days with planning for hematopoietic stem cell transplant ongoing. The ERT therapy has been well tolerated, with decreasing quantitative urine glycosaminoglycans. Long‐term follow up is required to determine whether treatment has been successful. This case demonstrates the utility of alternative testing methods to clarify the pathogenicity of variants and the clinical utility of obtaining a diagnosis antenatally in facilitating treatment in the neonatal period, and specifically highlights MPS‐VII as a treatable cause of NIHF.